Prophylaxis, Diagnosis, and Treatment Strategies of Gastric Cancer

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 1184

Special Issue Editors


E-Mail Website
Guest Editor
Department of Surgery—Surgery III, “Iuliu Hațieganu” University of Medicine and Pharmacy Cluj-Napoca, Croitorilor Street, No. 19-21, 400162 Cluj-Napoca, Romania
Interests: surgery

E-Mail Website
Guest Editor Assistant
Department of Surgery, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania
Interests: general surgery; liver resections; pancreatic surgery

Special Issue Information

Dear Colleagues,

Gastric cancer (GC) is a malignancy that is both aggressive and diverse. It is one of the most prevalent cancers in the world and a significant global health concern owing to the fact that it has a high death rate and poor prognosis.

There are two types of early screening for stomach cancer: mass screening, which is used on large populations, and opportunistic screening, which is used on people who are at risk.
Endoscopy and imaging are diagnostic methods that are utilized for the qualitative localization and staging of gastric cancer. These tools are considered to be the fundamental diagnostic tools for gastric cancer. Physical examination, laboratory testing, biopsy of metastases, diagnostic laparoscopic exploration, and study of abdominal lavage fluid are some of the other procedures that may be performed. The most fundamental method for pre-treatment staging is contrast-enhanced computer tomography (CT) of the thorax, abdomen, and pelvis. In addition, magnetic resonance imaging (MRI), laparoscopic exploration, and positron emission tomography (PET) are used as alternate methods for CT suspicion of liver metastases, peritoneal metastases, and lung metastases, respectively.

In the case of stomach cancer, the clinical stage should be taken into consideration while selecting the most suitable treatment strategy. Treatment using endoscopic techniques, including endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), is the method of choice for patients with in situ stomach. Open or laparoscopic surgery should be conducted on individuals who have localized cancer with curative intention. Patients with loco-regionally and systemically advanced gastric cancer who cannot undergo surgical options present a significant challenge in terms of treatment. It is now widely acknowledged that a combination of systemic drug chemo- or immunotherapy and local therapies, including palliative surgery, radiotherapy, and peritoneal perfusion, can be utilized in order to effectively treat these patients.

Improved early cancer detection, more appropriate monitoring of gastric premalignant lesions, more precise identification of patients who are likely to benefit from specific treatments, and a better understanding of gastric carcinogenesis in order to develop new therapeutic targets are all areas that need to be addressed in the field of gastric cancer.

We are looking forward to receiving articles on subjects related to the diagnosis, treatment, and prevention of stomach cancer for this Special Issue.

Dr. Andra Ciocan
Prof. Dr. Nadim Al Hajjar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • treatment
  • prevention
  • diagnosis
  • surveillance
  • follow-up
  • neoadjuvant therapy
  • prognosis
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 269 KB  
Article
The Effect of HER2 Status on Gastric Cancer Survival and the Clinical Implications of the HER2-Low Definition: A Retrospective Study
by Mehmet Uzun, Savas Gokcek, Melis Kilinc, Ferhat Ekinci, Tugay Avci, Atike Pinar Erdogan, Elif Atag and Ilkay Tugba Unek
Medicina 2025, 61(9), 1675; https://doi.org/10.3390/medicina61091675 - 15 Sep 2025
Viewed by 363
Abstract
Background and Objectives: HER-2 expression plays a critical role in the biological behavior and treatment of gastric cancer. With the emergence of HER-2-targeted therapies, classification into negative, low, and positive groups has gained clinical importance. The present study focused on assessing the [...] Read more.
Background and Objectives: HER-2 expression plays a critical role in the biological behavior and treatment of gastric cancer. With the emergence of HER-2-targeted therapies, classification into negative, low, and positive groups has gained clinical importance. The present study focused on assessing the link between HER-2 status and clinical–pathological variables, metastatic involvement, and overall survival (OS) among advanced gastric cancer patients. Materials and Methods: A total of 300 patients with advanced gastric adenocarcinoma were retrospectively analyzed. The mean age of the 300 patients included in the study was 61.8 years, and 70% of them were male. Based on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), patients were classified as HER-2-negative (IHC 0), HER-2-low (IHC 1+ or 2+/FISH-negative), or HER-2-positive (IHC 3+ or 2+/FISH-positive). Clinicopathological variables, metastatic sites, and OS were compared among groups using Pearson’s Chi-square, Fisher’s exact test, ANOVA, and Kaplan–Meier survival analysis. Results: Significant differences were observed among HER-2 subgroups in pathological subtype (p = 0.006), liver metastasis (p = 0.009), lung metastasis (p = 0.006), and other metastatic sites (p = 0.001). HER-2-positive patients demonstrated higher rates of adenocarcinoma histology and increased liver and lung metastases. In female patients, HER-2 status was significantly associated with lung (p = 0.001) and other metastases (p < 0.001). Median OS for the entire cohort was 9.83 months (95% CI: 8.29–11.36). HER-2-positive patients had a significantly longer OS (15.06 months) compared with HER-2-negative patients (8.73 months; p = 0.039). Conclusions: HER-2 status is an important predictor of metastatic behavior and survival in advanced gastric cancer. HER-2-positive patients display distinct metastatic patterns and improved outcomes, supporting the value of HER-2-targeted therapies. The HER-2-low group may represent a biologically and clinically relevant intermediate subtype requiring further investigation. Full article
(This article belongs to the Special Issue Prophylaxis, Diagnosis, and Treatment Strategies of Gastric Cancer)
Back to TopTop